– Public comment period now open until May 25th; Requests to make oral comment during public meeting also being accepted –

BOSTON, April 27, 2018 – The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for moderate-to-severe plaque psoriasis. The review will be open to public comment until May 25, 2018. Findings contained in this report are preliminary and subject to change based on additional stakeholder input and further analysis of data.

ICER previously reviewed treatments for plaque psoriasis in 2016. In addition to incorporating emerging clinical data for previously reviewed therapies, this condition update report includes new analyses of guselkumab (Tremfya®, Johnson & Johnson), tildrakizumab (Ilumya™, Sun Pharma/Merck), certolizumab pegol (Cimzia®, UCB), and risankizumab (AbbVie). Certolizumab pegol is currently approved for use in several other indications, including rheumatoid arthritis, and an approval decision for its plaque psoriasis indication is expected in May 2018. Risankizumab was added to the scope of the review based on feedback received during conversations with manufacturers and clinical experts; it was recently filed for FDA review.

ICER is committed to engaging with all stakeholders in a thorough and transparent manner. During this review update, ICER spoke with key patient groups, clinical experts, and manufacturers of drugs not included in ICER’s initial review. Public comments were also accepted on a Draft Scoping Document. The current draft report incorporates input received from patients, clinicians, and other stakeholders during each of these opportunities for engagement.

Submit a Public Comment: The Draft Evidence Report and Draft Voting Questions are now open to public comment until 5 PM ET on May 25, 2018. All stakeholders are invited to submit formal comments by email to publiccomments@icer.org.

Guidelines for submitting public comments, including formatting specifications, are available on ICER’s website. ICER’s Manufacturer Engagement Guide and Patient Participation Guide provide additional detail on what types of information may be most informative to the report.

ICER will review all comments and incorporate any necessary changes in the Evidence Report and Revised Voting Questions that will be posted on or about June 8, 2018. All comments and ICER’s response to comments will be posted publicly along with the Evidence Report.

Register for the Public Meeting: The Evidence Report will be the subject of a public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) on July 12, 2018 in Burlington, VT. During the meeting, the independent council will vote on key questions raised in the report.

Registration is now open for the public meeting or live webcast.

Register to Make an Oral Comment: During the public meeting, there will be a limited amount of time available for interested stakeholders to make an oral comment on the report. Requests to submit oral comments must be emailed to publiccomments@icer.org by 5 PM ET on May 25, 2018. Individuals who wish to deliver oral comments must separately register to attend the meeting.

For more information about registering for oral comment, please visit our website.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.